These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25603456)

  • 41. Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause.
    Perrone G; Capri O; Galoppi P; Brunelli R; Bevilacqua E; Ceci F; Ciarla MV; Strom R
    Gynecol Obstet Invest; 2009; 68(1):33-9. PubMed ID: 19349712
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
    Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
    Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Progesterone and progestins modulate beta-endorphin concentrations in the hypothalamus and in the pituitary of castrated female rats.
    Genazzani AR; Petraglia F; Bergamaschi M; Genazzani AD; Facchinetti F; Volpe A
    Gynecol Endocrinol; 1987 Mar; 1(1):61-9. PubMed ID: 2972169
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effect of tibolone on vascular markers of human female coronary arteries - comparison with estradiol/norethisterone].
    Mueck AO; Seeger H; Wallwiener D
    Zentralbl Gynakol; 2001 Nov; 123(11):648-54. PubMed ID: 11797164
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy.
    Meuwissen JH; Wiegerinck MA; Haverkorn MJ
    Maturitas; 1995 Feb; 21(2):121-5. PubMed ID: 7752949
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis.
    Heald A; Selby PL; White A; Gibson JM
    Am J Obstet Gynecol; 2000 Sep; 183(3):593-600. PubMed ID: 10992179
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ultrastructure study of postmenopausal endometria of tibolone, conjugated estrogen + medroxyprogesterone acetate and tamoxifen users.
    Nas T; Sargon MF; Celik HH; Keskin PO; Gürsoy RH; Biberoglu K
    Saudi Med J; 2007 Dec; 28(12):1917-9. PubMed ID: 18060233
    [No Abstract]   [Full Text] [Related]  

  • 48. A comparison of the central effects of different progestins used in hormone replacement therapy.
    Cagnacci A; Arangino S; Baldassari F; Alessandrini C; Landi S; Volpe A
    Maturitas; 2004 Aug; 48(4):456-62. PubMed ID: 15283939
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of short-term estradiol and norethindrone acetate treatment on the breasts of normal postmenopausal women.
    Cheng G; Butler R; Warner M; Gustafsson JÅ; Wilczek B; Landgren BM
    Menopause; 2013 May; 20(5):496-503. PubMed ID: 23615640
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of progesterone, medroxyprogesterone acetate, and norethisterone on growth factor- and estradiol-treated human cancerous and noncancerous breast cells.
    Krämer EA; Seeger H; Krämer B; Wallwiener D; Mueck AO
    Menopause; 2005; 12(4):468-74. PubMed ID: 16037763
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors.
    Skouby SO; Sidelmann JJ; Nilas L; Gram J; Jespersen J
    Climacteric; 2008; 11(6):489-97. PubMed ID: 18991076
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
    Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
    Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential effects of progestogens on breast cancer cell lines.
    Franke HR; Vermes I
    Maturitas; 2003 Dec; 46 Suppl 1():S55-8. PubMed ID: 14670646
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quercetin Induces Dose-Dependent Differential Morphological and Proliferative Changes in Rat Uteri in the Presence and in the Absence of Estrogen.
    Shahzad H; Giribabu N; Sekaran M; Salleh N
    J Med Food; 2015 Dec; 18(12):1307-16. PubMed ID: 26135605
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women.
    Lewandowski KC; Komorowski J; Mikhalidis DP; Bienkiewicz M; Tan BK; O'Callaghan CJ; Lewinski A; Prelevic G; Randeva HS
    J Clin Endocrinol Metab; 2006 Aug; 91(8):3123-30. PubMed ID: 16705077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of progestins.
    Mishell DR
    Postgrad Med; 1989 Apr; Spec No():84-8; discussion 89-90. PubMed ID: 2542913
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical background of women prescribed tibolone or combined estrogen + progestogen therapies: a UK MediPlus study.
    Wierik EJ; Hendricks PT; Boerstoel-Streefland M
    Climacteric; 2004 Jun; 7(2):197-209. PubMed ID: 15497909
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cognitive effects of long-term dydrogesterone treatment used alone or with estrogen on rat menopausal models of different ages.
    Liu J; Lin H; Huang Y; Liu Y; Wang B; Su F
    Neuroscience; 2015 Apr; 290():103-14. PubMed ID: 25637796
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of tibolone and 17beta-estradiol administration on the expression of zonula occludens-1, occludin, glial fibrillary acidic protein and c-fos levels in the brain cortex and hippocampus of female rats.
    Ceylan U; Akhan SE; Bastu E; Gungor-Ugurlucan F; Iyibozkurt AC; Topuz S
    Neuro Endocrinol Lett; 2012; 33(5):505-10. PubMed ID: 23090268
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes in protein tyrosine phosphatase type IVA member 1 and zinc finger protein 36 C3H type-like 1 expression demonstrate altered estrogen and progestin effect in medroxyprogesterone acetate-resistant and estrogen-independent breast cancer cell models.
    Pennanen PT; Sarvilinna NS; Purmonen SR; Ylikomi TJ
    Steroids; 2009; 74(4-5):404-9. PubMed ID: 19146866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.